| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Encequidar mesylate targets P-glycoprotein (P-gp/MDR1), an ATP-binding cassette (ABC) transporter that pumps a wide range of hydrophobic compounds out of cells. P-gp is overexpressed in many cancers and contributes to multidrug resistance by reducing the intracellular accumulation of chemotherapeutic drugs. By inhibiting P-gp, Encequidar mesylate blocks this efflux mechanism, restoring the sensitivity of cancer cells to chemotherapy.
|
|---|---|
| ln Vitro |
Encequidar (HM30181) therapy at concentrations of 0.1 or 1 nM led to a 20% and 42% reduction in survival with 100 nM and 1000 nM NSC 125973 administration, respectively [2].
In vitro, Encequidar mesylate inhibits P-gp-mediated efflux of various substrates, including chemotherapeutic agents such as paclitaxel, doxorubicin, and vincristine. It increases the intracellular accumulation of these drugs in P-gp-overexpressing cancer cell lines. Its potency as a P-gp inhibitor has been confirmed in various cell-based assays using fluorescent or radiolabeled P-gp substrates. |
| ln Vivo |
When Encequidar (HM30181) microcapsules and powder were given simultaneously, the plasma concentrations were greater; this difference was statistically significant and lasted between one and two hours. The AUC value was approximately 1.6 times higher and the Tmax of microcapsules was approximately 1.7 times faster than that of powder (2.5±0.6 vs. 4.3±0.9 h; 107.7±20.1 vs. 64.3±18.0 h ng/mL). Encequidar (HM30181) may have improved overall and absorbed more quickly in microencapsulated form because of its crystals changing into an amorphous state and its particle size being reduced, which has greatly increased its water solubility and dissolution [1].
In vivo, Encequidar mesylate has been shown to enhance the oral bioavailability and antitumor activity of co-administered chemotherapeutic agents. It has been evaluated in clinical trials for the treatment of various cancers, including breast cancer and colorectal cancer. By inhibiting intestinal and tumor P-gp, it increases the systemic exposure and intratumoral concentrations of chemotherapy drugs. |
| Enzyme Assay |
The primary in vitro assay for Encequidar mesylate is a P-gp inhibition assay using P-gp-overexpressing cell lines. Cells are incubated with a fluorescent P-gp substrate, such as rhodamine 123 or calcein-AM, in the presence of varying concentrations of the compound. The accumulation of the substrate is measured by flow cytometry or fluorometry, and the IC50 for P-gp inhibition is determined.
|
| Cell Assay |
Cellular assays for Encequidar mesylate involve treating P-gp-overexpressing cancer cell lines with the compound in combination with chemotherapeutic agents. The enhancement of drug accumulation is measured by assessing intracellular drug levels. The restoration of chemosensitivity is measured by assessing cell viability or apoptosis in the presence of the chemotherapeutic agent.
|
| Animal Protocol |
In vivo animal experiments for Encequidar mesylate have been conducted in mouse xenograft models of P-gp-overexpressing cancers. The compound is administered orally in combination with a chemotherapeutic agent, and its effects on tumor growth and drug accumulation in tumor tissue are assessed. Its pharmacokinetic properties and safety profile have also been evaluated.
|
| ADME/Pharmacokinetics |
Encequidar mesylate has a molecular weight of 665.79 g/mol and a molecular formula of C35H43N5O8S. It is an orally bioavailable compound. Its pharmacokinetic properties have been characterized in preclinical and clinical studies. It is typically administered orally and is well absorbed from the gastrointestinal tract.
|
| Toxicity/Toxicokinetics |
Encequidar mesylate has been evaluated in clinical trials for its safety and efficacy as a P-gp inhibitor. Common adverse effects may include gastrointestinal disturbances. Its safety profile has been established in clinical studies. It is a research compound and is not currently approved for clinical use.
|
| References |
|
| Additional Infomation |
See also: Ensequida mesylate (note moved to).
Encequidar mesylate (HM-30181) is a potent and selective inhibitor of P-glycoprotein (P-gp/MDR1) developed to overcome multidrug resistance in cancer therapy. It has been investigated in clinical trials as an adjunct to chemotherapy. The compound is available from various chemical suppliers for research purposes. |
| Molecular Formula |
C39H40N6O10S
|
|---|---|
| Molecular Weight |
784.834108352661
|
| Exact Mass |
784.252
|
| CAS # |
849675-87-2
|
| Related CAS # |
Encequidar;849675-66-7;Encequidar mesylate hydrochloride;2097125-58-9
|
| PubChem CID |
76971350
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
56
|
| Complexity |
1310
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PEKXWELLWNPUOK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C38H36N6O7.CH4O3S/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-361-5(2,3)4/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46)1H3,(H,2,3,4)
|
| Chemical Name |
N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide
methanesulfonate
|
| Synonyms |
HM-30181HM30181 HM 30181 HM-30181 mesylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~31.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.19 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2742 mL | 6.3708 mL | 12.7416 mL | |
| 5 mM | 0.2548 mL | 1.2742 mL | 2.5483 mL | |
| 10 mM | 0.1274 mL | 0.6371 mL | 1.2742 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA